Infigratinib, also known as, BGJ398 or NVP-BGJ398, is a pan FGFR kinase inhibitor, and is an orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. pan FGFR kinase inhibitor BGJ398 selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death.
FGFR Inhibitors Related Products:
PD173074; AZD4547; Danusertib; Brivanib alaninate; Pemigatinib; Lenvatinib; Lenvatinib mesylate; Nintedanib esylate; BLU9931; SKLB610; Roblitinib